Cargando…

Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study

PURPOSE: The objective of this study was to assess the safety and tolerability of preservative-free bilastine 0.6% ophthalmic solution after 8 weeks of once-daily administration in patients with allergic conjunctivitis (AC). PATIENTS AND METHODS: Multi-center, international, randomized, double blind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuna, Piotr, Jutel, Marek, Pulka, Grazyna, Tokarski, Slawomir, Arranz, Paula, Hernández, Gonzalo, Fernández Hernando, Nieves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994667/ https://www.ncbi.nlm.nih.gov/pubmed/36909350 http://dx.doi.org/10.2147/OPTH.S398168

Ejemplares similares

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
por: Ochoa, Dolores, et al.
Publicado: (2021)

Ocular Biodistribution of Once-Daily 0.6% Bilastine Eye Drops Reveals Highest Levels in Conjunctiva Up to 24 h Postadministration
por: Torrens, Inés, et al.
Publicado: (2022)

The safety and tolerability profile of bilastine for chronic urticaria in children
por: Papadopoulos, Nikolaos G., et al.
Publicado: (2019)

Bilastine for allergic rhinoconjunctivitis, urticaria
Publicado: (2022)

Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia
por: Cheong, Wai Kwong, et al.
Publicado: (2022)

Bilastine: new insight into antihistamine treatment
por: Ridolo, Erminia, et al.
Publicado: (2015)

Elucidation of Inverse Agonist Activity of Bilastine
por: Mizuguchi, Hiroyuki, et al.
Publicado: (2020)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria
por: Sadaba, Belen, et al.
Publicado: (2013)

Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients
por: Majmudar, Parag A., et al.
Publicado: (2014)

Comparative efficacy of bilastine, levocetirizine and desloratadine updosing in chronic urticaria
por: Staevska, Maria T
Publicado: (2016)

Effect of Bilastine on Diabetic Nephropathy in DBA2/J Mice
por: Verta, Roberta, et al.
Publicado: (2019)

Up-dosing with bilastine results in improved effectiveness in cold contact urticaria
por: Krause, K, et al.
Publicado: (2013)

Green quality by design HPLC approach for the simultaneous determination of Bilastine and Montelukast
por: Roshdy, Aya, et al.
Publicado: (2023)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency
por: Lasseter, Kenneth C., et al.
Publicado: (2013)

Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement
por: Mösges, Ralph, et al.
Publicado: (2016)

Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine
por: Wang, Xue Yan, et al.
Publicado: (2016)

Effectiveness of bilastine and fexofenadine among allergic Rhinitis patients in Ranchi, Jharkhand, India
por: Kumari, Abha, et al.
Publicado: (2022)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris, Timothy W, et al.
Publicado: (2011)

A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria
por: Shah, Bela, et al.
Publicado: (2022)

Application of a dual mechanistic approach to support bilastine dose selection for older adults
por: Kim, Chaejin, et al.
Publicado: (2021)

Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis
por: Singh Randhawa, Aranjit, et al.
Publicado: (2022)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen, Steven A, et al.
Publicado: (2013)

The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
por: Malhotra, Ranjan, et al.
Publicado: (2013)

Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria
por: Wolthers, Ole D.
Publicado: (2013)

Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria
por: Rodríguez, Mónica, et al.
Publicado: (2020)

Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions
por: Leceta, Amalia, et al.
Publicado: (2021)

Lack of Clinical Relevance of Bilastine-Food Interaction in Healthy Volunteers: A Wheal and Flare Study
por: Coimbra, Jimena, et al.
Publicado: (2022)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients [Corrigendum]
Publicado: (2013)

Concomitant bilastine and montelukast as additive therapy for seasonal allergic rhinoconjunctivits and mild‐to‐moderate asthma. The SKY study
por: Lavorini, Federico, et al.
Publicado: (2019)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas, Wolfgang, et al.
Publicado: (2011)

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016)

Magnetic Properties and the Electronic Structure of the Gd(0.4)Tb(0.6)Co(2) Compound
por: Sikora, Marcin, et al.
Publicado: (2020)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau, Joseph M, et al.
Publicado: (2021)

Bilastine vs. hydroxyzine: occupation of brain histamine H(1)-receptors evaluated by positron emission tomography in healthy volunteers
por: Farré, Magí, et al.
Publicado: (2014)

Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department
por: Leceta, Amalia, et al.
Publicado: (2017)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%
por: DeCory, Heleen H., et al.
Publicado: (2020)

Blindness resulting from orbital complications of ophthalmic zoster
por: Moniuszko, Anna, et al.
Publicado: (2015)

Safety and Tolerability of an Eye Drop Based on 0.6% Povidone–Iodine Nanoemulsion in Dry Eye Patients
por: Oliverio, Giovanni William, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8k8eg0t55ql3gleg1pp817gv1g